Relative Bioavailability of Two Different Formulations of Nerandomilast and Investigation of the Food Effect on New Formulation Following Oral Administration in Healthy Adult Male and Female Subjects (an Open-label, Randomised, Single-dose, Three-way Crossover Trial)
Latest Information Update: 20 Dec 2024
Price :
$35 *
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 Dec 2024 Status changed from active, no longer recruiting to completed.
- 19 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Oct 2024 Status changed from not yet recruiting to recruiting.